Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.35 |
| ▸ | DRD2 | P14416 | 3/20 | 0.35 |
| ▸ | DRD3 | P35462 | 3/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.33 |
| ▸ | PNMT | P11086 | 1/20 | 0.32 |
| ▸ | MLNR | O43193 | 2/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4148493 | 0.90 | MTOR (0.40) | KCNH2DRD3HRH3PIK3CAJAK2 | |
| SCHEMBL4128188 | 0.85 | KCNH2 (0.39) | KCNH2DRD2DRD3HRH3 | |
| SCHEMBL4141084 | 0.84 | JAK2 (0.42) | KCNH2DRD2DRD3HRH3PIK3CA | |
| SCHEMBL4141749 | 0.79 | MLNR (0.37) | DRD2DRD3JAK2PNMTMLNR | |
| SCHEMBL4130700 | 0.78 | ALDH1A1 (0.39) | DRD2DRD3PNMTMLNRCYP2D6 | |
| SCHEMBL4141846 | 0.77 | DRD2 (0.35) | KCNH2DRD2DRD3HRH3PNMT | |
| SCHEMBL4139662 | 0.76 | PNMT (0.35) | DRD2DRD3JAK2PNMTMLNR | |
| SCHEMBL4136050 | 0.75 | CASP3 (0.39) | KCNH2DRD2DRD3HRH3 | |
| SCHEMBL4143358 | 0.75 | USP30 (0.43) | KCNH2DRD3HRH3JAK2JAK3 | |
| SCHEMBL4136716 | 0.75 | HDAC4 (0.38) | DRD2DRD3PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | KCNH2 657/4885DRD2 197/4885DRD3 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.